Peptides for Perimenopause: What the Research Actually Says

Most of what's written about peptides for perimenopause sits in one of two unhelpful camps. The first treats peptides as a frontier alternative to hormone replacement therapy, with the implicit framing that HRT is dated or risky. The second dismisses peptides as wellness theater. Neither serves a woman trying to figure out what's happening to her body in her mid-forties and what to do about it.

The honest version is in the middle, and it depends entirely on which peptide you mean.

This piece walks through the peptides that come up most often in perimenopause conversations — GH-axis peptides, BPC-157, kisspeptin, collagen, and increasingly GLP-1 — and what the current research actually says about each. We'll also be clear about what these peptides do not do that hormone replacement therapy does, because the substitution framing is the most common way women in this category get steered toward the wrong thing.

What changes biologically in perimenopause#

Perimenopause is not "low estrogen." It's erratic estrogen, on a backdrop of slowly falling progesterone, rising FSH, and a steady decline in growth hormone (GH) that has been quietly underway since your late twenties.

The hormonal picture in plain terms:

• Progesterone falls first, often years before estrogen changes meaningfully. This drives the sleep disruption, anxiety, and shorter or unpredictable cycles that frequently mark the entry into perimenopause.
• Estradiol becomes volatile before it falls — large swings within and across cycles. Vasomotor symptoms (hot flashes, night sweats), mood lability, and cognitive fog often track these swings more than the overall level.
• FSH rises as the ovary becomes less responsive to it.
• Growth hormone secretion declines ~14% per decade after age thirty, with corresponding shifts in body composition (more central adiposity, less lean mass) and a hit to recovery, sleep quality, and skin elasticity.

The sex-specific layer is starting to be characterized at the mechanism level. A 2026 paper in PLoS One documented a potassium-linked metabolic axis governing IL-17A regulation specifically in females, distinct from the inflammation-mediated regulation seen in males — one of a growing number of studies pointing to female-specific physiology that the historical male-dominant trial record simply did not capture.

The takeaway for our purposes is structural: the literature on midlife metabolic, inflammatory, and hormonal change in women is genuinely sparse, and the peptide claims in this space have to be read against that thin evidentiary backdrop.

The honest framing#

Before we get into the specific peptides, the framing question matters: what role can any peptide reasonably play in a perimenopause plan?

The short answer: peptides are potential adjuncts to first-line care, not replacements for it. First-line for the major perimenopausal symptoms is — and as of mid-2026 still is — hormone replacement therapy, prescribed by a clinician trained in midlife women's health and matched to your specific risk profile. The post-WHI re-interpretation of the safety record makes HRT a substantially less complicated decision than it was a decade ago, particularly when started within ten years of menopause and below age sixty.

A peptide is in scope if (a) it has a coherent mechanism for a specific complaint, (b) there is at least some clinical evidence for that complaint, and (c) it is being added to a careful plan that already addresses sleep, protein intake, strength training, and stress — the four levers that outperform every peptide in this category.

If a peptide is being sold to you instead of HRT, or instead of the foundational basics, the framing is wrong.

GH-axis peptides — sermorelin, ipamorelin#

The GH-axis peptides — sermorelin and ipamorelin — are the ones perimenopausal women most often hear about in the context of midlife body composition shifts, sleep changes, and slowed recovery. The premise is that nudging the body's own growth hormone signaling, rather than replacing it, could partially offset the documented age-related GH decline.

The mechanism is real. Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH); ipamorelin is a ghrelin-receptor agonist that triggers a clean, pulsatile GH release without significantly affecting cortisol or prolactin. Both prompt the pituitary to do more of what it already does, rather than introducing exogenous GH.

The evidence is the harder conversation. Most of what is known about both peptides in this context comes from short, small clinical studies — often under fifty patients, often a few weeks long, often with composite endpoints that mix subjective and objective measures. There is enough signal to believe the mechanism translates from pituitary biology into measurable changes in body composition and sleep quality for some patients. There is not enough signal to predict whether a specific woman will respond, or how durable that response is at the year-or-more horizon perimenopause actually plays out over.

Where this lands: GH-axis peptides are reasonable to discuss with a careful provider as a possible adjunct for body composition or sleep complaints that haven't responded to the basics. They are not a treatment for perimenopausal vasomotor symptoms, mood lability, or bone protection — that's HRT's lane.

One critical distinction: CJC-1295 often gets mentioned in the same breath as sermorelin and ipamorelin. It carries a different and more cautious regulatory status, with adverse findings in nonclinical studies, and as of 2026 sits in a more restricted compounding pathway than the others. Do not let CJC-1295 get lumped in. A provider who treats the three as interchangeable is not paying attention.

BPC-157 for joint and tissue complaints#

The joint aches that arrive in perimenopause — knees, hips, the small joints of the hands, often a generalized increase in stiffness on waking — are real, common, and partly downstream of declining estrogen's effect on connective tissue. BPC-157 comes up frequently as a candidate for these complaints, often via gray-market sources marketed for tendon and ligament repair.

The honest picture on BPC-157 is this: the preclinical (animal) data is genuinely interesting — replicable healing effects on tendons, ligaments, and gut mucosa across multiple labs. The human data, however, consists of roughly three small studies, fewer than thirty subjects in total, none of which evaluated perimenopausal joint complaints specifically.

This puts BPC-157 in an awkward space. The mechanism is plausible. The animal evidence is meaningful. But to say "BPC-157 helps perimenopausal joint pain" is making a claim that no human study currently supports. A provider who frames it as a treatment for that indication is moving ahead of the data.

The regulatory status compounds the picture. BPC-157 was on the FDA's Category 2 "do not compound" list from late 2023 until April 2026, when the original nominations were withdrawn; a Pharmacy Compounding Advisory Committee review is scheduled for July 2026 to determine its formal 503A status. Outside the regulated compounding pathway, BPC-157 is widely sold as a "research chemical," which is not a legal pathway for human use.

Where this lands: BPC-157 is research-stage from a human-evidence standpoint and in transition from a regulatory standpoint. For perimenopausal joint complaints, the established interventions — strength training, weight management, estrogen-mediated tissue support via HRT if indicated, and direct rheumatologic evaluation if symptoms warrant it — sit on much stronger evidence.

Kisspeptin#

Kisspeptin is the most mechanistically interesting peptide in this category for perimenopause specifically, because it sits very far upstream in the reproductive hormone cascade. It is a neuropeptide that acts on the hypothalamus to trigger gonadotropin-releasing hormone (GnRH), which in turn drives LH and FSH. Small changes in kisspeptin signaling produce outsized downstream effects on the reproductive axis.

The question for perimenopause is whether kisspeptin modulation can smooth the hormonal volatility — the swings, not the absolute decline — that drives vasomotor symptoms, sleep disruption, and mood lability. The mechanism is plausible. The evidence is preliminary.

As we covered in Issue 02 of Anthivera Insider, the clinical literature for kisspeptin in perimenopausal women as of mid-2026 is at the early stage: small trials (typically under 100 patients), short durations (weeks rather than the years a chronic perimenopausal protocol would require), endpoints focused on hormonal markers rather than symptomatic improvement, and no long-term safety data — particularly around tumorigenicity in hormone-sensitive tissues, which is the question that mattered most for HRT in the post-WHI era.

Where this lands: Kisspeptin is the candidate to watch. It is not, as of mid-2026, an established perimenopausal therapy. A provider who frames it as one is moving faster than the science supports.

Collagen peptides#

Of every peptide in this article, oral collagen peptides sit on the strongest evidence base for perimenopausal women, and on the lowest risk profile. They are also, notably, a dietary supplement rather than a compounded prescription medicine.

Multiple human studies have demonstrated improvements in skin elasticity, hydration, and the appearance of fine lines with daily oral collagen peptide supplementation over 8-12 weeks, in populations that include perimenopausal women. There is also a coherent secondary literature on joint comfort with the same supplementation pattern.

The mechanism is well-characterized: ingested collagen peptides are absorbed as di- and tri-peptides, signaling to skin fibroblasts and chondrocytes to produce more endogenous collagen, rather than the peptides themselves becoming part of the new tissue.

Where this lands: A reasonable, low-risk option to discuss with a provider for the skin elasticity and joint comfort complaints that often accompany perimenopause. The supplement aisle versus prescription distinction matters — quality varies, and a clinician can point you to specific products with reasonable quality control rather than the noisiest marketed brand.

GLP-1 in the perimenopause conversation#

GLP-1 receptor agonists have become an increasingly common part of the midlife conversation, prescribed off the standard endocrine path for the central adiposity and metabolic shifts that many women see in perimenopause.

Two pieces of 2026 research that landed this week are worth surfacing:

• A 2026 paper decoding the hallmarks of GLP-1RA weight-loss super-responders is starting to characterize the patient profile most likely to respond robustly to this class of drug — useful work for a midlife population in which response variability is high.
• A May 2026 JACC case report identified a potential association between GLP-1 receptor agonists and hyponatremia, a safety signal worth carrying into the consult conversation if you are considering GLP-1 use, particularly alongside other medications that affect sodium balance.

In preclinical work, a May 2026 Diabetologia paper documented a GLP-1 + estradiol combination therapy showing additive effects on autoimmune diabetes in a mouse model. That is preclinical, but it points to the kind of estrogen-aware peptide research that has been missing from the field and may meaningfully reshape it over the next five years.

Where this lands: GLP-1s are not the focus of this article and are not strictly "peptide therapy" in the off-label sense the rest of this category lives in, but if you are reading this you are probably also thinking about them. The same questions that apply to any prescription decision apply here — and a careful midlife provider should be able to discuss them.

What peptides do not do that HRT does#

This is the section that decides the framing.

Hormone replacement therapy has a body of evidence for perimenopausal women — measured in decades, evaluated and re-evaluated through the post-WHI complications, and re-emerged as the established first-line option for several specific outcomes — that no peptide in this article approaches.

Specifically, none of the peptides discussed above has demonstrated evidence for:

• Vasomotor symptom control (hot flashes, night sweats) — HRT remains the most effective intervention.
• Bone density protection — estrogen's role in bone is well-characterized; no peptide here substitutes.
• Genitourinary syndrome of menopause (vaginal dryness, urinary symptoms) — local estrogen is highly effective and safe.
• Cognitive outcomes in the perimenopausal window specifically.

If any of these are your primary complaint, a peptide is not the answer. A peptide may complement an HRT plan, or sit alongside it for a specific complaint that HRT doesn't fully address. It does not replace it.

The framing of "natural" peptides versus "synthetic" HRT is a marketing distinction, not a clinical one. Both are compounded or manufactured molecules; the difference is the depth of evidence.

Questions to bring to a Menopause Society Certified Practitioner#

For perimenopause specifically, the credential to look for in a provider is Menopause Society Certified Practitioner (MSCP) — formerly NAMS Certified Menopause Practitioner. Not every gynecologist is one; the credential signals specific training in the hormonal and clinical management of the menopausal transition.

Bring these questions to a first consult, whether the provider is an MSCP, an internist with women's-health focus, or a careful peptide-clinic clinician:

1. What are you treating, and what's the evidence base for the specific intervention you're recommending — in midlife women specifically?
2. If you're recommending a peptide, why this peptide for my complaint, rather than HRT or a first-line treatment?
3. What baseline labs are you running before prescribing? What are you watching for over time?
4. What's the current regulatory status of this peptide, and which compounding pharmacy will prepare it?
5. What would make you tell me a peptide isn't the right adjunct for me?
6. If I'm a candidate for HRT, are we starting there before adding anything else?

A provider whose answers to all six are clear, specific, and willing to draw the boundary between evidence-based first-line care and adjunctive options is the provider you want. A provider who reaches for a peptide stack as the lead intervention for a perimenopausal complaint is not.

The full first-consult checklist — twelve questions formatted for printing — lives in our free guide. Bring it. The decision stays with you and your doctor; this article is here to help make sure you arrive at that conversation with the right map.